Case Reports in Medicine

Case Reports in Medicine / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 3701016 | 4 pages | https://doi.org/10.1155/2019/3701016

Myocarditis Caused by Brucella melitensis in the Absence of Endocarditis: Case Report and Review of the Literature

Academic Editor: Frans J. Walther
Received11 Nov 2018
Accepted22 Jan 2019
Published10 Feb 2019

Abstract

Brucellosis remains an important public health problem with endemic characteristics in many countries. Brucellosis can affect almost all organs and systems of human body. Cardiac complications are unusual, occurring in less than 2% of patients and usually manifest as endocarditis. We present the case of a 21-year-old Caucasian man, who was admitted to the University Hospital of Patras, Western Greece, with fatigue, fever up to 39°C, and retrosternal pain. Musculoskeletal, genitourinary, gastrointestinal, hematologic, nervous, skin, and mucous membranes and respiratory complications have been reported in several cases of brucellosis. Development of myocarditis is a highly rare complication of brucellosis, particularly in the absence of concomitant endocarditis. Clinicians should be aware of this clinical entity especially in endemic areas as appropriate antibiotic treatment is life-saving and may prevent serious cardiologic disorders.

1. Introduction

Brucellosis remains an important public health problem with endemic characteristics in many countries [1]. It is a worldwide zoonosis, with Mediterranean basin, the Middle East, India, Mexico, and Central and South America being the areas with the highest prevalence [2]. Brucellosis can affect almost all organs and systems of human body and should always be considered in the differential diagnosis in patients presenting with chronic fever combined with a history of contact with animals or animal products [3].

Cardiac complications from brucellosis are unusual, occurring in less than 2% of patients and usually manifest as endocarditis [4]. Unlike endocarditis, which is the most common cardiac complication, acute pericarditis and myocarditis without associated endocardial involvement are rare, and very few cases have been reported from countries with high prevalence of the disease [5]. Herein, we present an unusual case of a patient with myocarditis due to Brucella in the absence of concomitant endocarditis.

2. Case Presentation

A 21-year-old Caucasian man was admitted to the University Hospital of Patras, Western Greece, with fatigue, fever up to 39°C, and retrosternal pain. He denied anorexia, night sweats, and generalized malaise. No significant past medical history was reported. There were no risk factors for HIV infection, no recent travel outside Greece, and no exposure to animals. The patient denied smoking and drinking, and also no allergies were noted.

On physical examination, the temperature was 39.0°C, the heart rate was 90°bpm with sinus rhythm, and the blood pressure was 120/80 mmHg. The patient was respiratory stable (respiratory rate 16/min and oxygen saturation 98% on room air). No cervical or supraclavicular lymphadenopathy was identified. There were no murmurs, rubs, or gallops, and the lungs were clear on auscultation and percussion. The abdomen was nondistended, with normal active bowel sounds and mildly tender in the midepigastrium but without rebound or guarding. No liver or spleen enlargement was noted. No abnormalities like clubbing, cyanosis, or edema were found on all extremities. The rest of the examination was unremarkable.

Electocardiography (ECG) revealed a sinus rhythm with ST elevation (ST 2 mm in I, II, aVL, and V4–V6) (Figure 1). Furthermore, laboratory tests showed a low platelet count 134.000 (normal range 150.000–400.000 Κ/μl), raised aspartate aminotransferase (193 U/L, upper normal limit (UNL) 40 U/L) and alaninoaminotranferase (42 U/L 40 U/L), high CPK levels (2166 mg/dl, upper normal limit 190 mg/dl) with CPK-ΜΒ lower than 10% of total CPK (112 mg/dl), troponine (ΤnI) 48.51 ng/ml, and CRP 4.60 mg/dl. The hemogram was normal (Table 1). Chest X-ray image did not reveal any abnormalities. Blood and urine cultures were taken on admission. The transthoracic echocardiography Doppler showed wall motion abnormalities and absence of pericardial effusion. Accordingly, a cardiac MRI using delayed enhancement was performed (Figures 2 and 3) revealing recent myocardial damage with edema and fibrosis in the middle and upper left and right lower wall and increased left ventricular dimensions with normal systolic function.  In addition, cardiac MRI revealed overriding of the right ventricle with normal systolic function


Variable (unit)Patient resultReference value

Hemoglobin (g/dl)13.912–15
Platelets (Κ/μL)134.000150.000–400.000
Leukocytes (K/Μl)4.824.0–11
SGOT (U/l)193<40
SGPT (U/l)42<40
CPK/CPK-ΜΒ (U/l)2166/112<140
ΤnI (ng/ml)48.51<14

Serology for Influenza A and B, parvovirus B19, EBV, and CMV, ECHO virus, Coxsackie virus, HSV, VSV, and adenovirus, Coxiella burnetii, Chlamydia, Leptospira spp., and Mycoplasma pneumoniae were negative. On day 3 of hospitalization, Brucella melitensis was isolated from two consecutive blood cultures. The Brucella serum agglutination test (SAT) was positive >1/1280, so a diagnosis of Brucella-related myocarditis was made. Treatment with oral rifampicin (900 mg once daily) and doxycycline (100 mg twice daily) along with intravenous gentamycin (320 mg once daily) was immediately commenced. Gentamycin was administered for ten days. The patient recalled that he had consumed unpasteurized goat cheese a month ago. After five days of treatment, the patient was clinically improved, asymptomatic, and fever was regressed. No signs of cardiac arrythmias or other ECG abnormalities on serial ECGs, during hospitalization, were noted. On discharge day, all laboratory tests were normal (Table 2). Patient had a total antibiotic course with Doxycycline and rifampicin for 6 months.


Variable (unit)Patient resultReference value

Hemoglobin (g/dl)1412–15
Platelets (Κ/μL)184.000150.000–400.000
Leukocytes (K/Μl)4.854.0–11
SGOT (U/l)58<40
SGPT (U/l)34<40
CPK/ΜΒ (U/l)109/10<140
ΤnI (ng/ml)<14

3. Discussion

Brucellosis is a zoonosis infecting the human, having a worldwide distribution especially in the developing countries [6]. The microorganism is frequently transmitted to humans via consumption of infected unpasteurized dairy products and direct contact with infected animal tissues. The prevalence of the disease is high in the Arabian Peninsula and Mediterranean countries [4]. Clinical presentations of brucellosis are various. The most common symptoms of the disease are fever (95%), anorexia (90%), fatigue (90%), smelly perspiration (80%), arthralgia (25–50%), and weight loss. Less common symptoms and signs of the disease are swelling of the joints (15%), splenomegaly (20%), and lymphadenopathy of the inguinal area (10–15%). Bronchitis, pleurisy, emphysema, pulmonary abscess, and cardiac involvement are very uncommon [5].

Infection from Brucella species has a wide range of clinical complications. Musculoskeletal, genitourinary, gastrointestinal, hematologic, nervous, skin, and mucous membranes and respiratory complications have been reported in several cases. Cardiovascular involvement is a rare complication and usually is presented as endocarditis, remaining the principal cause of mortality in the course of brucellosis. It usually affects the aortic valve and typically requires immediate surgical valve replacement [4].

However, endocarditis is the most common cardiac complication of the disease. A few case reports have been published, illustrating different forms of Brucella endocarditis. In the absence of concomitant Brucella-related endocarditis, development of myocarditis is extremely rare. According to Colmenero et al., only 1.54% of 530 brucellosis cases had cardiac involvement, with only one patient having myocarditis [7]. Cases of pericarditis or myocarditis without simultaneous endocarditis are reported sporadically [6, 8, 9]. PubMed database search for articles published until October 2018 using keywords myocarditis and Brucella revealed only a few reports with myocarditis in the absence of endocarditis (Table 3).


PublicationGenderAgeTreatmentFollow-up

Gur et al. [10]Woman25 yStreptomycin and tetracyclineRelapse after 4 months
Lubani et al. [11]Boy10 yTetracycline for two weeks
Streptomycin for three weeks
Two-year follow-up showed no relapse
Jubber et al. [12]Man55 yDoxycycline and rifampicinNo follow-up
Efe et al. [4]Woman51 yStreptomycin for 3 weeks
Doxycycline for 6 weeks
3-month follow-up: asymptomatic
Elkiran et al. [13]Girl3 monthsGentamycin, Bactrim, and rifampicinFour-month follow-up: no relapse
Pandit et al. [6]Woman32 yStreptomycin and doxycyclineWorsened and died due to pulmonary odema
Gatselis et al. [2]Man34 yStreptomycin for 3 weeks
Doxycycline and rifampicin
One-year follow-up: no symptoms, no relapse
Gatselis et al. [2]Man17 yStreptomycin for 3 weeks
Doxycycline and rifampicin
One-year follow-up: no symptoms, no relapse
Adid et al. [8]Man32 yStreptomycin for 2 weeks3-month follow-up: no relapse
Doxycycline and rifampicin for 12 weeks
Abid et al. 2012 [8]Man20 yCotrimoxazole and rifampicinNo follow-up
Khorasani and Farrokhnia 2014 [5]Man22 yCotrimoxazole, doxycycline, and rifampicin for 3 monthsTwo-month follow-up: asymptomatic
Pandit et al. 2010 [6]Man27 yDoxycycline, rifampicin for 12 weeks, and gentamycin for 10 daysAfter several months, the patient was asymptomatic

In the current case report, no involvement of cardiac valves was observed in repeated echocardiography. The diagnosis of Brucella myocarditis was based on with positive blood cultures, positive Brucella serum agglutination test, and pericardial effusion in echocardiography, associated with typical symptoms and myocardial involvement as well. The mechanism of cardiac damage is not clear, but it may be due to the direct effect of the microorganism or local deposit of immunocomplexes.

Patients suffering from Brucella myocarditis usually respond to antibiotic therapy well. According to previous reports, streptomycin (1 g/day for 3 weeks) and doxycycline (200 mg/day for 6 weeks) or rifampicin (600 mg/day for 6 weeks) and doxycycline (200 mg/day for 6 weeks) are the appropriate therapy regimens [4]. Our patient was successfully treated with oral rifampicin (900 mg once daily) and doxycycline (100 mg twice daily) along with intravenous gentamycin (320 mg once a day). Gentamycin was administered for 10 days totally, while doxycycline and rifampicin were given for 6 months. This prolonged administration was decided after consultation of the Hospital’s Infectious Diseases Consultation team due to the severity of the disease and the myocardial involvement. Furthermore, no clear guidelines related to this complication of brucellosis exist.

In conclusion, development of myocarditis is a highly rare complication of brucellosis, particularly in the absence of concomitant endocarditis. Clinicians should be aware of this clinical entity especially in endemic areas as appropriate antibiotic treatment is life-saving and may prevent serious cardiologic disorders.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

  1. K. Farzin, A. H. Keshteli, M. Behjati, M. Salehi, and A. E. Naeini, “An unusual presentation of brucellosis, involving multiple organ systems,with low agglutinating titers: a case report,” Journal of medical case Reports, vol. 1, no. 1, p. 53, 2007. View at: Publisher Site | Google Scholar
  2. N. Gatselis, K. P. Makaritsis, I. Gabranis, A. Stefos, K. Karanikas, and G. N. Dalekos, “Unusual cardiovascular complications of btucellosis presenting in two men: two case reports and a review of the literature,” Journal of medical case Reports, vol. 5, no. 1, p. 22, 2011. View at: Publisher Site | Google Scholar
  3. B. Hussain and F. A. Tipoo Sultan, “A rare cardiac manifestation of Brucellosis (RCD CODE: VIII),” Journal of Rare Cardiovascular Diseases, vol. 3, no. 4, pp. 129–132, 2017. View at: Publisher Site | Google Scholar
  4. C. Efe, T. Can, M. Ince, H. Tunca, F. Yildiz, and E. Sennaroglu, “A rare complication of Brucella infection: myocarditis and heart failure,” Internal Medicine, vol. 48, no. 19, pp. 1773-1774, 2009. View at: Publisher Site | Google Scholar
  5. A. A. Khorasani and M. Farrokhnia, “A case of myopericarditis: very rare complication of Brucellosis,” Archives of Clinical Infectious Diseases, vol. 9, no. 3, Article ID e18256, 2014. View at: Publisher Site | Google Scholar
  6. V. R. Pandit, S. Seshadri, R. Valsalan, S. Bahuleyan, K. E. Vandana, and P. Kori, “Acute brucellosis complicated by fatal myocarditis,” International Journal of Infectious Diseases, vol. 14, no. 4, pp. 358–360, 2010. View at: Publisher Site | Google Scholar
  7. J. D. Colmenero, J. M. Reguera, F. Martos et al., “Complications associated with Brucella melitensis infection: a study of 530 cases,” Medicine, vol. 75, no. 4, pp. 195–211, 1996. View at: Publisher Site | Google Scholar
  8. L. Abid, Z. Frikha, S. Kallel et al., “Brucella myocarditis: a rare and life-threatening cardiac complication of brucellosis,” Internal Medicine, vol. 51, no. 8, pp. 901–904, 2012. View at: Publisher Site | Google Scholar
  9. J. M. Riviera, B. F. Garcia, F. A. Gomez, A. Grilo, and L. Gutierrez, “Brucella pericarditis,” Infection, vol. 16, no. 62, 1998. View at: Google Scholar
  10. H. Gur, D. Gefel, and R. Tur-Kaspa, “Transient electrocardiographic changes during two episodes of relapsing brucellosis,” Postgraduate Medical Journal, vol. 60, no. 706, pp. 544-545, 1984. View at: Publisher Site | Google Scholar
  11. M. Lubani, D. Sharda, and I. Helin, “Cardiac manifestations in brucellosis,” Archives of Disease in Childhood, vol. 61, no. 6, pp. 569–572, 1986. View at: Publisher Site | Google Scholar
  12. A. S. Jubber, D. R. L. Gunawardana, and A. R. Lulu, “Acute pulmonary edema in Brucella myocarditis and interstitial pneumonitis,” Chest, vol. 97, no. 4, pp. 1008-1009, 1990. View at: Publisher Site | Google Scholar
  13. O. Elkiran, G. Kocak, C. Karakurt, and C. Kuzucu, “Brucellamyocarditis in a 3-month-old: probable transplacental transmission,” Annals of Tropical Paediatrics, vol. 30, no. 3, pp. 225–228, 2013. View at: Publisher Site | Google Scholar

Copyright © 2019 Maria Lagadinou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1148 Views | 326 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.